Combination therapy with neuroprotectants and thrombolytics in acute ischaemic stroke

European Neurology

Volumn 40, Issue 1, 1998, Pages 1-8

  Steiner, Thorsten ^a   Hacke, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerebral ischaemia; Combination therapy; Neuroprotection; Stroke; Thrombolysis

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ANTIBODY; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; CITICOLINE; CLOMETHIAZOLE; DEXTRORPHAN; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; GAVESTINEL; GLUTAMATE RECEPTOR ANTAGONIST; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; NEUROPROTECTIVE AGENT; NICARDIPINE; NIMODIPINE; SCAVENGER; TIRILAZAD; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLERGY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DELIRIUM; DIPLOPIA; DRUG COMBINATION; DRUG EFFICACY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATION; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEPHROTOXICITY; NEUROPROTECTION; NYSTAGMUS; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY FAILURE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STROKE; VERTIGO;

BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MODELS, NEUROLOGICAL; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY;

EID: 0031815260     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007947     Document Type: Review

References (61)

1. La Vecchia C, Levi F: Trends in cerebrovascular mortality in Western and Eastern Europe. Eur Neurol 1994;34:301-305.
2. Intredavik B, Bakke F, Solberg R, Rockseth R, Haaheim LL, Holme I: Benefit of a stroke unit: A randomized controlled trial. Stroke 1991;22: 1026-1031.
3. Jorgensen HS, Nakayama H, Raaschou HO, Larsen K, Hubbe P, Olsen TS: The effect of a stroke unit: Reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost: A community-based study. Stroke 1995;26:1178-1182.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne M-H: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
5. Silver B, Weber J, Fisher M: Medical Therapy for Ischemic Stroke. Clin Neuropharmacol 1996;19:101-128.
6. Hossmann KA: Viability threshold and the penumbra of focal ischemia. Ann Neurol 1994; 36:557-565.
7. Steiner T, Willig V, Hacke W: Thrombolytic therapy in acute ischaemic stroke; in Caplan LR (ed): Cerebrovascular Ischaemia - Investigation and Management. London, Med-Orion Publishing, 1996, pp 319-326.
8. NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
9. Hacke W, Zeumer H, Ferbert A, Brückmann H, Del Zoppo G: Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216-1222.
10. von Kummer R, Forsting M, Sartor K, Hacke W: Intravenous tissue plasminogen activator in acute stroke; in Hacke W. del Zoppo GJ, Hirschberg M (eds): Thrombolytic Therapy in Acute Stroke. Berlin, Springer, 1991, pp 161-167.
11. Hallenbeck JM, Dutka AJ: Background review and current concepts of reperfusion injury. Arch Neurol 1990;47:1245-1254.
12. Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN: Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am J Physiol 1987;253: H699-H703.
13. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1: 623-634.
14. Small DL, Buchan AM: Mechanisms of cerebral ischemia: Intracellular cascades and therapeutic interventions. J Caridothorac Vase Anesth 1996;10:139-146.
15. Iversen LL, Lees KR: Excitatory amino acid antagonists. Baillière's Clin Anaestesiol 1996; 10:481-496.
16. Buchan AM, Lesiuk H. Barnes KA, Li H, Huang Z-G, Smith KE, Xue D: AMPA antagonists: Do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993;24:148-152.
17. Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia. Parts I and II: Pathophysiology. J Neurosurg 1992;77:169-184.
18. Hess DC, Zhao W, Carroll J, Mc Eachin M, Buchanan K: Increased expression of ICAM-1 during reoxygenation in brain endothelial cells. Stroke 1994;25:1463-1468.
19. Kochanek PM, Hallenbeck JM: Polymorphonuclear leucocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1991;23:1367-1379.
20. Harlan J: Leukocyte-endothelial interactions. J Am Soc Hematol 1985;65:513-525.
21. Hallenbeck JM, Frerichs KU: Stroke therapy: It may be time for an integrated approach. Arch Neurol 1993;50:768-770.
22. Baringa M: Finding new drugs to treat stroke. Science 1996;272:664-666.
23. Dorman PJ, Counsell CE, Sandercock PAG: Recently developed neuroprotective therapies for acute stroke: A qualitative systematic review of clinical trials. CNS Drugs 1996;5:457-474.
24. Fisher M: Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995;35:3-7.
25. Limburg M, Horn J, Vermeulen M: Very early nimodipine in stroke (VENUS). Abstr 22nd Int Joint Conf on Stroke and Cerebral Circulation. Anaheim, American Heart Association, 1997, CT5, p2.
26. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T, for the INWEST Study Group: Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204-210.
27. Choi DW: Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev 1990;2:105-142.
28. Trembley B: Clinical potential for the use of neuroprotective agents: A brief overview. Ann NY Acad Sci 1995;1-20.
29. Vender JR, Nair SN, Lehmann JC: Pharmacological potential for compounds acting at NMDA receptors: Update 1995. Exp Opin Invest Drugs 1995;4:475-485.
30. Zornow HM, Prough DS: Neuroprotective properties of calcium-channel blockers. New Horizons 1996;4:107-114.
31. Olney JW: Neurotoxicity of NMDA receptor antagonists: An overview. Psychopharmacol Bull 1994;30:533-540.
32. Lesko LM, Turnni R, Hall D, Paumé D, Harding C for Boehringer Ingelheim Pharmaceutical: A pivotal phase III efficacy and safety study of Cerestat (Aptiganel HCL/CNS 1102) in acute stroke patients: 1996 update. Abstr 22nd Int Joint Conf on Stroke and Cerebral Circulation. Anaheim. American Heart Association, 1997, CT16, p2.
33. Davis SM, Albers GW, Diener H-C: Termination of acute stroke studies involving selfotel treatment. Lancet 1997;349:32.
34. Haley EC, for the Glaxo Wellcome North American GAIN Investigators: Glycine Antagonist in Neuroprotection-1 (GAIN-1). Abstr 22nd Int Joint Conf on Stroke and Cerebral Circulation. Anaheim, American Heart Association, 1997, CT3, p2.
35. Snape MF, Baldwin HA, Cross AJ, Green AR: The effects of clomethiazole and nimodipine on cortical infarct area after focal cerebral ischemia in the rat. Neuroscience 1993;53:837-844.
36. Wahlgren NG: The Clomethiazole Acute Stroke Study (CLASS). II. Results of a randomised controlled study of clomethiazole versus placebo in 545 acute stroke patients classified as total anterior circulation syndrome (TACS) (abstract). Cerebrovasc Dis 1997;7:19.
37. Wahlgren NG: The Clomethiazole Acute Stroke Study (CLASS). I. Results of a randomised controlled study of clomethiazole versus placebo in 1,360 acute stroke patients (abstract). Cerebrovasc Dis 1997;7:19.
38. Hall ED, Pazara KE, Braughler JM: Effects of tirilazad mesylate on postischemic brain lipid peroxidation and recovery of extracellular calcium in gerbils. Stroke 1991;22:361-366.
39. Xue D, Slivka A, Buchan AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 1992;23:894-899.
40. The STIPAS Investigators: Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25:418-423.
41. Haley EC, Alves W, Kassell NF, Johnston KC, Ford G, Solenski N, Shreve DL, Wilkinson SS, Clements S, Cuccia E: A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-1458.
42. Pharmacia and Upjohn RANTTAS Investigators: Randomized trial of high dose tirilazad in acute stroke (RANTTAS II). Abstr 22nd Int Joint Conf on Stroke and Cerebral Circulation. Anaheim, American Heart Association, 1997, CT4, p2.
43. Scheller D, KoIb J, Zacharias E, De Ryck M, Van Reempts J, Clincke B, Tegtmeier F: Extracellular changes of glutamate in the perinfarcted zone: Effect of lubeluzole. J Cereb Blood Flow Metab 1995;15:S379.
44. Lesage AS, De loore KL, Osikowska-Evers B, Peeters L, Leysen JF: Lubeluzole, a novel neuroprotectant, inhibits the glutamate-activated NOS pathway. Soc Neurosci Abstr 1994;20: 185.
45. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J for the Lubeluzole International Study Group: Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke 1996;27:76-81.
46. Diener HC, Kaste M, Hacke W: Lubeluzole in acute ischemic stroke: International trial (abstract). J Neurol Sci 1997;150:5199.
47. Grotta J for the US and Canadian Lubeluzole Ischemic Stroke Study Group: Lubeluzole treatment of acute ischemic stroke. Stroke 1997;28:2338-2346.
48. Polmar S, Sherman D for Boehringer Ingelheim Pharmaceutical: Enlimomab (Anti ICAM-1) Acute Stroke Trial (EAST). Abstr 22nd Int Joint Conf on Stroke and Cerebral Circulation. Anaheim. American Heart Association, 1997, CT11, p2.
49. D'Orlando KJ, Sandage B Jr: Citicoline (CDP-choline): Mechanisms of action and effects in ischemic brain injury. Neurol Res 1995;17: 281-284.
50. Clark WM, Portland OR, Warach SJ for the Citicoline Study Group: Randomized dose response trial of citicoline in acute ischemic stroke patients (abstract). Neurology 1996;46: A425.
51. Grinspan JB, Stern J, Franceschini B, Yasuda T, Pleasure D: Protein growth factors as potential therapies for central nervous system demyelinative disorders. Ann Neurol 1994;36: S140-142.
52. Patterson SL, Grady MS, Bothwell M: Nerve growth factor and a fibroblast growth factor-like neurotrophic activity in cerebrospinal fluid of brain injured human patients. Brain Res 1993;605:43-49.
53. Fisher M, Meadows ME, Do T, Weiss J, Trubetskoy V, Charette M, Finkelstein S: Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995;15:953-959.
54. Barsan WG, Brott TG, Broderick JP, Haley EC, Marier RJ: Time of hospital presentation in patients with acute stroke. Arch Intern Med 1993;153:2558-2561.
55. Grand M, Rudolf J, Schmülling S, Stenzel C, Neveling M, Heiss WD: Can the NINDS results be transferred into daily routine? (abstr 83). Stroke 1998;29:288.
56. Umemura K, Wada K, Uematsu T, Nakashima M: Evaluation of the combination of tissue plasminogen activator, SUN9216, and a thromboxane A2 receptor atagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 1993;24:1077-1082.
57. Meden P, Overgaard K, Pedersen H, Boysen G: Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolie stroke. Cerebrovasc Dis 1996;6:141-148.
58. Meden P, Overgaard K, Sereghy T, Boysen G: Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sci 1993;119: 209-216.
59. Zivin JA, Mazzarella V: Tissue plasminogen activator plus glutamate antagonists improves outcome after embolic stroke. Arch Neurol 1991;48:1235-1240.
60. Bowes MP, Rothlein R, Fagan SC, Zivin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995;45:815-819.
61. Uematsu D, Araki N, Greenberg JH, et al: Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology 1991;41:88-94.